Dokumentanzeige 

Zur Kurzanzeige

Título
Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.
dc.contributor.authorReboredo, Mercedes
dc.contributor.authorChang, Haisul C. Y.
dc.contributor.authorBarbero, Roberto
dc.contributor.authorRodríguez-Ortigosa, Carlos M
dc.contributor.authorPérez-Vizcaíno, Francisco
dc.contributor.authorMorán Benito, Asunción 
dc.contributor.authorGarcía Domingo, Mónica 
dc.contributor.authorBanales, Jesus M.
dc.contributor.authorCarreño, Norberto
dc.contributor.authorAlegre, Félix
dc.contributor.authorHerrero, Ignacio
dc.contributor.authorQuiroga, Jorge
dc.contributor.authorPrieto, Jesús
dc.contributor.authorSangro, Bruno
dc.date.accessioned2024-11-13T07:52:45Z
dc.date.available2024-11-13T07:52:45Z
dc.date.issued2013
dc.identifier.citationReboredo M, Chang HC, Barbero R, Rodríguez-Ortigosa CM, Pérez-Vizcaíno F, Morán A, García M, Banales JM, Carreño N, Alegre F, Herrero I, Quiroga J, Prieto J, Sangro B. Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure. PLoS One. 2013;8(1):e52683. doi: 10.1371/journal.pone.0052683. Epub 2013 Jan 16. PMID: 23341903; PMCID: PMC3547109.es_ES
dc.identifier.urihttp://hdl.handle.net/10366/160607
dc.description.abstractOnly a limited proportion of patients needing pharmacological control of portal hypertension are hemodynamic responders to propranolol. Here we analyzed the effects of zolmitriptan on portal pressure and its potential interaction with propranolol. Zolmitriptan, propranolol orbothwere tested intwo ratmodelsof portal hypertension: commonbileduct ligation(CBDL) andCCl4-inducedcirrhosis. Intheseanimalswemeasureddifferenthemodynamicparameters including portalvenouspressure,arterial renal flow,portalbloodflowandcardiacoutput.Wealsostudiedthechanges insuperior mesenteric artery perfusionpressure and inarterial wall cAMP levels inducedby zolmitriptan, propranolol or both. Moreover,wedeterminedtheeffectofsplanchnicsympathectomyontheresponseofPVPtozolmitriptan. Results:Inbothmodelsofportalhypertensionzolmitriptaninducedadose-dependenttransientdescentofportalpressure accompaniedbyreductionofportalflowwithonlyslightdecreaseinrenalflow. Incirrhoticrats,splanchnicsympathectomy intensifiedandprolongedzolmitriptan-inducedportalpressuredescent.Also,propranololcausedmoreintenseanddurable portalpressurefallwhencombinedwithzolmitriptan.Mesentericarteryperfusionpressurepeakedforabout1minupon zolmitriptanadministrationbutshowednochangewithpropranolol.Howeverpropranololenhancedandprolongedthe elevation inmesenteric artery perfusionpressure inducedby zolmitriptan. In vitro studies showed that propranolol prevented the inhibitory effects of b2-agonists on zolmitriptan-induced vasoconstriction and the combination of propranololandzolmitriptansignificantlyreducedtheelevationofcAMPcausedbyb2-agonists. Conclusion:Zolmitriptanreducesportalhypertensionandnon-selectivebeta-blockerscanimprovethiseffect.Combination therapydeservesconsiderationforpatientswithportalhypertensionfailingtorespondtonon-selectivebeta-blockers.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectZolmitriptanes_ES
dc.subjectPortal hypertensiones_ES
dc.subjectHaemodynamic parameterses_ES
dc.subjectBeta-blockerses_ES
dc.subject.meshOxazolidinones *
dc.subject.meshPortal Pressure *
dc.subject.meshBody Weight *
dc.subject.meshCommon Bile Duct *
dc.subject.meshLigation *
dc.subject.meshLiver Cirrhosis *
dc.subject.meshCyclic AMP *
dc.subject.meshPropranolol *
dc.subject.meshSplanchnic Circulation *
dc.subject.meshTryptamines *
dc.subject.meshVasodilation *
dc.subject.meshAdrenergic beta-Antagonists *
dc.subject.meshDrug Synergism *
dc.subject.meshDrug Therapy *
dc.subject.meshCarbon Tetrachloride *
dc.subject.meshCatecholamines *
dc.subject.meshHypertension *
dc.subject.meshLypressin *
dc.subject.meshPerfusion *
dc.subject.meshRegional Blood Flow *
dc.subject.meshRats *
dc.subject.meshAnimals *
dc.subject.meshRenal Artery *
dc.subject.meshSympathectomy *
dc.subject.meshAntihypertensive Agents *
dc.titleZolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1371/journal.pone.0052683
dc.subject.unesco3209 Farmacologíaes_ES
dc.identifier.doi10.1371/journal.pone.0052683
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid23341903
dc.identifier.essn1932-6203
dc.volume.number8es_ES
dc.issue.number1es_ES
dc.page.initiale52683es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decstetracloruro de carbono *
dc.subject.decscirrosis hepática *
dc.subject.decsvasodilatación *
dc.subject.decsconducto colédoco *
dc.subject.decslipresina *
dc.subject.decscatecolaminas *
dc.subject.decspresión portal *
dc.subject.decsarteria renal *
dc.subject.decspropranolol *
dc.subject.decssimpatectomía *
dc.subject.decsflujo sanguíneo regional *
dc.subject.decsligadura *
dc.subject.decshipertensión *
dc.subject.decstriptaminas *
dc.subject.decsantagonistas adrenérgicos beta *
dc.subject.decsperfusión *
dc.subject.decsanimales *
dc.subject.decsantihipertensivos *
dc.subject.decspeso corporal *
dc.subject.decsoxazolidinonas *
dc.subject.decsratas *
dc.subject.decsAMP cíclico *
dc.subject.decscirculación esplácnica *
dc.subject.decssinergismo farmacológico *
dc.subject.decsfarmacoterapia *


Dateien zu dieser Ressource

Thumbnail
Name:
Reboredo et al., 2013.pdf
Größe:
560.6Kb
Format:
PDF
Öffnen

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional